Target intelligence / Profile preview

Rift Valley fever virus nucleocapsid protein (RVFV N)

Target
RVFV N
Molecular classification
Viral protein, RNA-binding protein
01

Overview

The Rift Valley fever virus nucleocapsid protein (N protein) is a critical structural component of the Rift Valley fever virus (RVFV), a member of the Phenuiviridae family. Its primary biological role is to encapsidate the tripartite negative-sense single-stranded RNA genome, protecting it from host cell nucleases and forming the ribonucleoprotein (RNP) complex necessary for viral replication and transcription (UniProt P03518). The N protein also interacts with the viral L protein (polymerase) and has been implicated in modulating the host immune response by suppressing interferon production (PubMed: 22740399). In the context of disease, RVFV causes severe outbreaks in livestock and humans, ranging from self-limiting flu-like symptoms to fatal hemorrhagic fever or encephalitis. Because the N protein is essential for the viral life cycle and is highly conserved among RVFV strains, it is a primary target for the development of antiviral drugs and diagnostic assays (PubMed: 31434287). Therapeutic strategies focus on small molecules that disrupt N-protein oligomerization or its ability to bind viral RNA, thereby halting viral assembly and propagation (PubMed: 25653454).

Other names
NucleoproteinN proteinRVFV NucleoproteinRift Valley fever virus N protein
02

Mechanism of action

Inhibition of viral RNA encapsidation, disruption of nucleocapsid oligomerization, and interference with the interaction between the nucleocapsid protein and the viral RNA-dependent RNA polymerase (L protein).

03

Biological functions

Viral genome encapsidationRNA bindingViral replicationViral transcriptionRibonucleoprotein complex formationHost immune evasion
04

Disease associations

InfectionRift Valley fever
05

Safety considerations

High mutation rate of RNA viruses leading to drug resistancePotential for off-target effects on host RNA-binding proteinsRequirement for high-containment facilities (BSL-3) for live virus validation
06

Interacting drugs

Favipiravir

2 more in the full profile.

07

Biomarkers

RVFV N antigen (detected via ELISA)Anti-N IgM antibodiesAnti-N IgG antibodies

Beyond the preview

Go deeper on Rift Valley fever virus nucleocapsid protein (RVFV N).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rift Valley fever virus nucleocapsid protein (RVFV N).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call